432 related articles for article (PubMed ID: 7600845)
1. Clinical reversal of drug resistance.
Goldstein LJ
Curr Probl Cancer; 1995; 19(2):65-124. PubMed ID: 7600845
[TBL] [Abstract][Full Text] [Related]
2. Immunosuppressors as multidrug resistance reversal agents.
Morjani H; Madoulet C
Methods Mol Biol; 2010; 596():433-46. PubMed ID: 19949935
[TBL] [Abstract][Full Text] [Related]
3. Multidrug resistance: molecular mechanisms and clinical relevance.
Ling V
Cancer Chemother Pharmacol; 1997; 40 Suppl():S3-8. PubMed ID: 9272126
[TBL] [Abstract][Full Text] [Related]
4. Reversal of multidrug resistance by Marsdenia tenacissima and its main active ingredients polyoxypregnanes.
To KKW; Wu X; Yin C; Chai S; Yao S; Kadioglu O; Efferth T; Ye Y; Lin G
J Ethnopharmacol; 2017 May; 203():110-119. PubMed ID: 28363522
[TBL] [Abstract][Full Text] [Related]
5. Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein.
Sikic BI; Fisher GA; Lum BL; Halsey J; Beketic-Oreskovic L; Chen G
Cancer Chemother Pharmacol; 1997; 40 Suppl():S13-9. PubMed ID: 9272128
[TBL] [Abstract][Full Text] [Related]
6. Molecular mechanisms of multidrug resistance in cancer chemotherapy.
Nooter K; Stoter G
Pathol Res Pract; 1996 Jul; 192(7):768-80. PubMed ID: 8880878
[TBL] [Abstract][Full Text] [Related]
7. New silicon compounds as resistance modifiers against multidrug-resistant cancer cells.
Molnar J; Mucsi I; Nacsa J; Hevér A; Gyémánt N; Ugocsai K; Hegyes P; Kiessig S; Gaal D; Lage H; Varga A
Anticancer Res; 2004; 24(2B):865-71. PubMed ID: 15161039
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms of drug resistance in chemotherapy for urogenital carcinoma.
Naito S; Yokomizo A; Koga H
Int J Urol; 1999 Sep; 6(9):427-39. PubMed ID: 10510888
[TBL] [Abstract][Full Text] [Related]
9. New potent verapamil derivatives that reverse multidrug resistance in human renal carcinoma cells and in transgenic mice expressing the human MDR1 gene.
Mickisch GH; Merlino GT; Aiken PM; Gottesman MM; Pastan I
J Urol; 1991 Aug; 146(2):447-53. PubMed ID: 1677434
[TBL] [Abstract][Full Text] [Related]
10. RNA expression of breast cancer resistance protein, lung resistance-related protein, multidrug resistance-associated proteins 1 and 2, and multidrug resistance gene 1 in breast cancer: correlation with chemotherapeutic response.
Burger H; Foekens JA; Look MP; Meijer-van Gelder ME; Klijn JG; Wiemer EA; Stoter G; Nooter K
Clin Cancer Res; 2003 Feb; 9(2):827-36. PubMed ID: 12576456
[TBL] [Abstract][Full Text] [Related]
11. Molecular changes to HeLa cells on continuous exposure to cisplatin or paclitaxel.
Takara K; Obata Y; Yoshikawa E; Kitada N; Sakaeda T; Ohnishi N; Yokoyama T
Cancer Chemother Pharmacol; 2006 Dec; 58(6):785-93. PubMed ID: 16534613
[TBL] [Abstract][Full Text] [Related]
12. Expression of multidrug resistance 1 (MDR1), multidrug resistance-related protein 1 (MRP1), lung resistance protein (LRP), and breast cancer resistance protein (BCRP) genes and clinical outcome in childhood acute lymphoblastic leukemia.
Kourti M; Vavatsi N; Gombakis N; Sidi V; Tzimagiorgis G; Papageorgiou T; Koliouskas D; Athanassiadou F
Int J Hematol; 2007 Aug; 86(2):166-73. PubMed ID: 17875533
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological strategies for overcoming multidrug resistance.
Nobili S; Landini I; Giglioni B; Mini E
Curr Drug Targets; 2006 Jul; 7(7):861-79. PubMed ID: 16842217
[TBL] [Abstract][Full Text] [Related]
14. P-glycoprotein in adult hematologic malignancies.
Marie JP
Hematol Oncol Clin North Am; 1995 Apr; 9(2):239-49. PubMed ID: 7642463
[TBL] [Abstract][Full Text] [Related]
15. Anticancer drug sensitivity and expression of multidrug resistance markers in early passage human sarcomas.
Hoffmann J; Schmidt-Peter P; Hänsch W; Naundorf H; Bunge A; Becker M; Fichtner I
Clin Cancer Res; 1999 Aug; 5(8):2198-204. PubMed ID: 10473106
[TBL] [Abstract][Full Text] [Related]
16. Multidrug resistance in pediatric malignancies.
Chan HS; DeBoer G; Haddad G; Gallie BL; Ling V
Hematol Oncol Clin North Am; 1995 Apr; 9(2):275-318. PubMed ID: 7642465
[TBL] [Abstract][Full Text] [Related]
17. Relevance of multidrug resistance in the age of targeted therapy.
Türk D; Szakács G
Curr Opin Drug Discov Devel; 2009 Mar; 12(2):246-52. PubMed ID: 19333870
[TBL] [Abstract][Full Text] [Related]
18. Multidrug resistance in breast cancer: a meta-analysis of MDR1/gp170 expression and its possible functional significance.
Trock BJ; Leonessa F; Clarke R
J Natl Cancer Inst; 1997 Jul; 89(13):917-31. PubMed ID: 9214671
[TBL] [Abstract][Full Text] [Related]
19. Reversing agents for ATP-binding cassette drug transporters.
Lee CH
Methods Mol Biol; 2010; 596():325-40. PubMed ID: 19949930
[TBL] [Abstract][Full Text] [Related]
20. Zafirlukast antagonizes ATP-binding cassette subfamily G member 2-mediated multidrug resistance.
Sun YL; Kathawala RJ; Singh S; Zheng K; Talele TT; Jiang WQ; Chen ZS
Anticancer Drugs; 2012 Sep; 23(8):865-73. PubMed ID: 22614107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]